Tech Company Financing Transactions
Araris Biotech Funding Round
Araris Biotech closed a $2.8 million investment round on 5/5/2023. Backers included private investors.
Transaction Overview
Company Name
Announced On
5/5/2023
Transaction Type
Venture Equity
Amount
$2,786,000
Round
Undisclosed
Investors
Proceeds Purpose
The non-dilutive funding will be used to develop and advance the company's pipeline of ADC candidates, developed using its proprietary linker technology, towards the clinic.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Riedhofstrasse 11
Zurich, 8804
CH
Zurich, 8804
CH
Phone
Undisclosed
Website
Email Address
Overview
Araris Biotech AG, a spin-off company from the Paul Scherrer Institute (PSI) and ETH Zurich, is pioneering the development of a novel, proprietary antibody-drug conjugate (ADC)-linker technology. Our linker platform enables payload attachment to 'off-the-shelf' antibodies in one step without needing to re-engineer or reduce antibodies, resulting in highly homogenous, stable and potent ADC therapies.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Philipp Spycher
Co-Founder
Isabella Toller
Browse more venture capital transactions:
Prev: 5/5/2023: Glass venture capital transaction
Next: 5/5/2023: DearEmployee venture capital transaction
Share this article
Where The Data Comes From
We do our best to record funding rounds that are announced publicly. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs